SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Corcept Reports Positive Phase 2 Data for Lifyorli Combination

Corcept reported positive Phase 2 data for a Lifyorli combination in platinum-resistant ovarian cancer.

CORT

Related stories